Citations

Clear

134 citation(s) found for "Alam, M M".

Brain-Only Versus GI-Only Synucleinopathy: A Comprehensive Autopsy Study With Both IHC and SAA
Orru, Christina D., Beach, Thomas G., Adler, Charles H., Shill, Holly A., Driver-Dunckley, Erika, Mehta, Shyamal H. , Atri, Alireza, Lorenzini, Ileana , Qiji, Sanaria H., Intorcia, Anthony J., Hughson, Andrew G., Groveman, Bradley R. , King, Samantha, Parveen, Sabiha , Caughey, Byron, Serrano, Geidy E , Orru, Christina Doriana , Beach, Thomas G. , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika , Atri, Alireza , Hughson, Andrew G. , Alam, Parvez , Vascellari, Sarah , Caughey, Byron W. , Serrano, Geidy E.

Mayo Clinic

No container title available | March 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.18.26348355 | PMID 41929295 Get It

ABSTRACT Braak and others have proposed that Lewy body pathology (LBP) in Parkinson’s disease (PD) may arise not only in the brain but alternatively from an initial site in the gastrointestinal (GI) tract with subsequent passage to the central nervous system CNS through the vagus nerve or other routes. We tested this hypothesis by using both immunohistochemistry (IHC) and RT QuIC a form of alpha synuclein seed amplification assay (SAA) to detect alpha synuclein LBP in samples from selected brain regions and 10 GI tract sites taken from autopsies of 50 PD subjects and 128 elderly subjects without parkinsonism or dementia including 34 with IHC identified CNS incidental Lewy body disease (ILBD) and 94 with no Lewy body IHC pathology detected (NLB). A positive SAA or IHC result was restricted to the GI tract in only 2 subjects while LBP by either SAA or IHC was restricted to the brain in 11 subjects. To fairly compare GI-only with brain-only synucleinopathy, however, we would have to do SAA on brain samples from all ILBD and NLB cases in at least 4 critical brain regions: olfactory bulb, medulla, pons, and amygdala. Further SAA of brain regions is estimated, based on the proportional results to date, to potentially identify 21 additional brain-only LBP subjects, for a total of 32, if it were done on all of the NLB subjects. From this brain-only LBP is estimated to be 16 times more common than GI-only LBP. To assess the clinical impact of SAA-positive GI sites we found that the number of positive sites per subject is significantly correlated with UPDRS motor score and SCOPA-AUT GI related scores including those for salivation, straining, constipation, and bowel movement.
Understanding the Triangles: A Practical Roadmap of the Cavernous Sinus
Alam, Yasaman, Leonel, Luciano C. P. C., Plou, Pedro, Peris-Celda, Maria, Bonis, Alessandro De, Plou, Pedro , Serioli, Simona , Peris‐Celda, Maria

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 27, 2026 | Volume: 87 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1818661 Get It

A meta-analysis of the haemodynamic and echocardiographic changes following arteriovenous fistula ligation in chronic kidney disease patients
Einieh, M, Zaldumbide, J M, Alam, M, Rezende, V, Felix, L Ferreira, Diaz, Jose Matias Zaldumbide , Zaldumbide Diaz, Jose Matias , Einieh, Mahmoud

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.1462 Get It

Abstract Introduction Arteriovenous fistulas (AVF) are the preferred method for establishing long-term, reliable vascular access in patients undergoing haemodialysis for end-stage renal disease. However, previous research has shown that high-flow AVFs may increase cardiovascular strain after kidney transplantation, often necessitating fistula closure in these patients. Currently, there is no established guideline for managing high-flow fistulas in post-transplant patients with stable kidney function, and the haemodynamic effects of AVF closure are unknown. Objective This study aims to perform a systematic review and meta-analysis of haemodynamic and echocardiographic changes following AVF closure compared to AVF persistence. Methods We systematically searched PubMed, Cochrane, and Web of Science up to December 2024 for observational studies or randomised controlled trials (RCTs), including patients with chronic kidney disease (CKD) undergoing AVF ligation versus maintenance. Key parameters indicative of cardiac and renal function were assessed. The statistical analysis was performed on Cochrane’s RevMan tool, using random effects model. Heterogeneity was assessed through I² statistics. Results We included 841 patients from 12 studies, 10 observational and 2 RCTs. 406 (48.2%) patients underwent AVF ligation, and follow-up ranged from 3 to 62.5 months. Arteriovenous fistula ligation was associated with a decrease in left ventricular mass index (MD -10.88 g/m²; 95% CI -17.84, -3.93; p=0.007; I²=8%; Figure 1A), left ventricular end diastolic volume (MD -19.55 ml; 95% CI -20.52, -18.58; p=<0.00001; I²=0%; Figure 1B), and cardiac index (MD -0.56 1/min/m²; 95% CI -1.05, -0.07; p=0.03; I²=70%; Figure 1C). There was no significant difference in posterior wall thickness (MD -0.46 mm; 95% CI -1.32, 0.4; p=0.23; I2=57%), left ventricular ejection fraction (MD -0.12%; 95% CI -3.01, 2.77; p=0.92; I2=50%), and left ventricular end systolic volume (MD -6.28 ml; 95% CI -12.64, 0.07; p=0.05; I²=52%). Systolic blood pressure (MD -2.47 mmHg; 95% CI -9.57, 4.63; p=0.41 I²=62%; Figure 2A) and diastolic blood pressure (MD 1.54 mmHg; 95% CI -3.12, 6.19; p=0.44 I²=69%) were not significantly different between groups. Patients undergoing AVF ligation had a significant decrease in serum creatinine (MD -0.12 mg/dl; 95% CI -0.22, -0.03; p=0.02; I²=0%; Figure 2B), however, no difference was seen for eGFR (MD 2.78 ml/min/1.73 m²; 95% CI -3.25, 8.81; p=0.24; I²=2%; Figure 2C) between groups. Conclusion In chronic kidney disease patients, AVF ligation was associated with improved the patient’s overall echocardiographic parameters and reduced the risk of remodelling, with no significant blood pressure changes. Although creatinine seems to improve in this patient population, no differences were seen on eGFR. Further randomised studies are needed to better characterise the haemodynamic changes associated with AVF ligation.
Abstract WP112: Predictors of 90-Day Recurrent Stroke in Patients with High-Grade Intracranial Atherosclerotic Stenosis: A subgroup analysis from the BIORISK-ICAS Study
Stretz, Christoph, Lewis, Skylar, Chahien, Dalia, Alam, Shaista , Halabi, Tarek El, Guerrero, Chris, Walsh, Hadley A., Frontera, Jennifer, baker, rich, Nguyen, Thanh, Tunguturi, Ajay, Khan, Muhib, Klaas, James P. , Liebeskind, D, Morsi, Rami, Helenius, Johanna, Khatri, Pooja, Freitas, Joao, Aziz, Yasmin, Rothstein, Aaron, Shu, Liqi , Reda, Mahasen, Tountopoulou, Argyro , Khasawneh, Mohammad W , Klein, Piers, Havenon, Adam de, Almiri, William , Prabhakaran, S, AlMajali, Mohammad, Zaidat, Osama, Qdais, Ahmad Abu, McCullough-Hicks, Margy, Elangovan, Cheran, Sousa, João André, Romoli, Michele, Henninger, Nils, Marto, Joao Pedro, Agarwal, Ayush, Kasab, Sami Al, Yaddanapudi, Sridhara , Krishnaiah, Balaji , Sousa, Diana Aguiar de, Yaghi, Shadi, Henninger, Nils , Sousa, Diana Aguiar de , Henninger, Nils , Aguiar de Sousa, Diana , Khan, Fahad , Stretz, Christoph , Alam, Shaista, Halabi, Tarek El , Sloane, Kelly L , Heldner, Mirjam R. , Antonenko, Kateryna , Baker, Richard, Khan, Muhib , Marrone, Nicole L. , Siegler, James E. , Morsi, Rami Z. , Aziz, Yasmin , Rothstein, Aaron , Reda, Mahasen , Prabhakaran, Shyam , McCullough‐Hicks, Margy , Elangovan, Cheran , Romoli, Michele , Marto, João Pedro , Kasab, Sami Al

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.wp112 Get It

Background: High-grade intracranial atherosclerosis (ICAS) is associated with an elevated risk of recurrent ischemic stroke, particularly in patients with severe stenosis (70–99%). Identifying predictors of early recurrence can inform risk stratification and guide treatment strategies. Methods: The Biomarkers and Recurrence Risk in Symptomatic Intracranial Arterial Stenosis (BIORISK-ICAS) study is a multicenter, international, retrospective cohort analysis pooling data from 35 comprehensive stroke centers. We included hospitalized adult patients with symptomatic ICAS, defined as 50–99% stenosis of an intracranial artery (intracranial vertebral, basilar, distal ICA, or M1 MCA), confirmed by vascular imaging and associated with a qualifying ischemic event. Patients with only high-grade stenosis (70-99%) were included in this analysis. The primary outcome was to determine predictors of recurrent ischemic stroke in the territory of the symptomatic artery within 90 days of the index event. Baseline demographic, clinical, and imaging characteristics were recorded. Multivariable Cox proportional hazards regression with stepwise selection (p < 0.1) was used to identify independent predictors of recurrence; model discrimination was assessed using Harrell’s C-statistics. Results: Among 2,050 patients, 1,476 had high-grade (70-99%) symptomatic ICAS. The mean age was 67 ± 12.5 years, and 767 (55%) were male. Most patients were non-Hispanic (90.1%), taking dual antiplatelet therapy (77.8%), and statins (94.5%). Recurrent stroke occurred in 160 patients (10.8%) within 90 days. In multivariable Cox model, independent predictors of recurrence included atrial fibrillation (HR 2.05; 95% CI, 1.26–3.33; p = 0.004), hyperlipidemia (HR 1.57; 95% CI, 1.10–2.24; p = 0.014), diabetes mellitus (HR 1.36; 95% CI, 0.98–1.88; p = 0.064), and home use of dual antiplatelet therapy (HR 1.60; 95% CI, 1.01–2.54; p = 0.043)(Harrell’s C-statistic=0.62). In patients who underwent perfusion(n=402), mistmatch >10seconds were associated with increased recurrence (HR 1.80; 95% CI 0.95-3.38, p=0.07) and atrial fibrillation (HR 2.06: 95% CI 0.03-4.60, p=0.78) though did not reach statistical significance. Conclusion: In this population, diabetes, hyperlipidemia, atrial fibrillation, and prior use of dual antiplatelet therapy were associated with increased risk of 90-day recurrent ischemic stroke. Perfusion imaging may help identify high-risk patients who could benefit from intensified secondary prevention.
Abstract DP310: Dual Antiplatelet versus Anticoagulant-Plus-Antiplatelet Therapy in Symptomatic Intracranial Atherosclerosis: A Multicenter Comparative Study
Rehman, M. Aemaz Ur, Yaghi, Shadi, Kasab, Sami Al, Qdais, Ahmad Abu, Yaddanapudi, Sridhara , Sultana, Sabiha , Khan, Muhib, Malik, Maarij , Klaas, James P. , Guerrero, Christopher Leon, Velez, Faddi Saleh, Pinto, Camila, McCullough-Hicks, Margy, Cooper, Dawson C , Pillai, Abhiram Parameswaran, Hariharan, Praveen, Alam, Shaista , Antonenko, Kateryna, Almiri, William , Rothstein, Aaron, Krishnaiah, Balaji , Elangovan, Cheran, Agarwal, Ayush, Romoli, Michele, Nicola, Marrone, Vozzi, Stefano, Ghannam, Malik, Dibas, Mahmoud I., Marto, Joao Pedro, AlMajali, Mohammad, Sousa, Diana Aguiar de, Soares, Mafalda Delgado, Lima, Anicléia Rodrigues de, Tountopoulou, Argyro , Havenon, Adam de, Henninger, Nils, Helenius, Johanna, Khasawneh, Mohammad W , Klein, Piers, Shu, Liqi , Khatri, Pooja, Nguyen, Thanh N., Liebeskind, D, Bakradze, Ekaterina, Henninger, Nils , Sousa, Diana Aguiar de , Henninger, Nils , Aguiar de Sousa, Diana , Khan, Fahad , Yaghi, Shadi , Kasab, Sami Al , Sultana, Sabiha, Khan, Muhib , Leon Guerrero, Christopher R , Velez, Faddi G. Saleh , Owens, Cameron , Pinto, Camila, McCullough‐Hicks, Margy , Hariharan, Praveen , Alam, Shaista, Heldner, Mirjam R. , Antonenko, Kateryna , Rothstein, Aaron , Elangovan, Cheran , Romoli, Michele , Marrone, Nicola , Ghannam, Malik , Dibas, Mahmoud, Marto, João Pedro , Simpkins, Alexis N. , Soares, Mafalda , Lima, Amanda, Siegler, James E. , VASILOPOULOU, SOFIA, Klein, Piers , Bakradze, Ekaterina

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp310 Get It

Introduction: Intracranial atherosclerosis (ICAS) is a leading cause of ischemic stroke (IS) worldwide and carries a high risk of recurrence. Current guidelines favor 90 days of dual antiplatelet therapy (DAPT) for severe symptomatic ICAS, but recurrence remain high. Limited data suggest possible benefit of single antiplatelet plus anticoagulation (SAPT+AC). We compared the effectiveness and safety of DAPT versus SAPT+AC. We hypothesized that DAPT would lower 90-day recurrent IS risk without significantly increasing bleeding. Methods: This substudy of the Biomarkers and Recurrence Risk in Symptomatic Intracranial Arterial Stenosis (BIORISK-ICAS) included patients from 35 centers (Jan 2019–Jun 2024) with symptomatic 50–99% ICAS in the intracranial internal carotid, vertebral, basilar, or M1 segment of the MCA, presenting ≤72 hours from last known well. The primary efficacy outcome was recurrent IS in the same vascular territory at 90 days; the primary safety outcome was severe bleeding (symptomatic intracranial hemorrhage or major extracranial bleeding). Categorical variables were compared using χ 2 and continuous variables with the Student's t test; multivariable Cox regression adjusted for key covariates. Results: Of 2050 BIORISK-ICAS patients, 1658 met criteria (DAPT n=1499; SAPT+AC n=159). Mean age was 67 vs. 73 years, and 44% were women. At 90 days, recurrent IS occurred in 121 DAPT patients (8.07%) vs. 13 SAPT+AC patients (8.17%); unadjusted HR 0.83 (95% CI, 0.50–1.36; p=0.46). After adjustment for age, diabetes, coronary heart disease, atrial fibrillation, active smoking, and borderzone infarct, the adjusted HR was 0.99 (95% CI, 0.52–1.86; p=0.97). Severe bleeding occurred in 34 DAPT patients (2.26%) and 5 SAPT+AC patients (3.14%); unadjusted HR 0.79 (95% CI, 0.28–1.85; p=0.50), adjusted HR 0.66 (95% CI, 0.21–2.09; p=0.47). Conclusions: In patients with symptomatic ICAS, DAPT and SAPT+AC were associated with similar risks of 90-day recurrent ischemic stroke and severe bleeding. Well-powered randomized trials are needed to determine the optimal antithrombotic regimen in this high-risk population.
Sirolimus-Coated Versus Paclitaxel-Coated Balloons for Coronary Artery Disease: A Grade Assessed Systematic Review and Meta-Analysis
Sajjad, Fatima , Khattak, Asad Iqbal , Farhan, Kanza, Arshad, Ayesha , Afridi, Abdullah, Shahid, Iqra, Imtiaz, Zeeshan , Naveed, Hammad, Alam, Umama , Henna, Fathimathul, Riaz, Zoya, Khattak, Fazia , Waqas, Saad Ahmed, Ahmed, Raheel, Farhan, Kanza , Afridi, Abdullah , Ali, Muhammad Abdullah , Shahid, Iqra , Henna, Fathimathul , Waqas, Saad Ahmad

Mayo Clinic

Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine | January 14, 2026 | Volume: 25 | Issue: 2 | Pages: e0415

10.1097/hpc.0000000000000415 | PMID 41533835 Get It

Despite advances in percutaneous coronary procedures, in-stent restenosis remains a significant challenge. Although sirolimus- and paclitaxel-coated balloons are promising alternatives, their comparative safety and efficacy remain uncertain. PubMed, Embase, and Cochrane databases were searched using relevant keywords from inception until August 2025. A total of 11 studies (7 randomized controlled trials and 4 observational cohort studies) were included, comprising 3633 participants overall. The primary outcomes assessed were target lesion revascularization and target lesion failure. Meanwhile, the Secondary outcomes included stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events, survival, binary restenosis, and angiographic endpoints (acute gain, diameter stenosis, in-segment late lumen loss, in-lesion late lumen loss, and in-segment minimal lumen diameter). Interstudy heterogeneity was assessed using I ² and X ² statistics ( I ²>50% = significant heterogeneity). Interstudy heterogeneity was low for most outcomes, including all primary clinical endpoints, with moderate heterogeneity observed only for select angiographic measures (notably in-segment late lumen loss and diameter stenosis). Statistical analysis was conducted using R software and RStudio (version 4.4.2), with a P value of < 0.05 indicating statistical significance. This meta-analysis examined studies that compared paclitaxel-coated balloon (PCB) versus standard balloon [sirolimus-coated balloon (SCB)] angioplasty. Regarding primary outcomes, there were no notable variations in target lesion failure [risk ratio (RR), 1.08, 95% CI, 0.90–1.29, P = 0.36] or target lesion revascularization (RR, 1.16, 95% CI, 0.98–1.37, P = 0.08). With all aggregated estimates being nonsignificant, secondary outcomes such as stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events, and survival were similar between groups. Angiographic endpoints revealed no discernible variations in late lumen loss (in-lesion and in-segment), acute gain, or diameter stenosis. Nonetheless, the SCB group’s minimal lumen diameter was significantly smaller than that of the PCB group (MD, −0.08 mm, 95% CI, −0.14 to −0.01, P = 0.02). In treating coronary in-stent restenosis, SCB and PCBs show similar overall safety and effectiveness; lesion-specific angiographic variations indicate that customized selection may improve patient outcomes.
The Utility of Artificial Intelligence Platforms for Post‐Operative Mohs Micrographic Surgery Questions: A Blinded Expert Panel Evaluation
Shelton, Eva, Patel, Janmesh , Alam, Murad , Bar, Anna, Rohrer, Thomas A., Ruiz, Emily S. , Wysong, Ashley, Yu, Siegrid S., Tolkachjov, Stanislav N., Shelton, Eva M , Bar, Anna, Tolkachjov, Stanislav N.

Mayo Clinic

International Journal of Dermatology | January 7, 2026 | Volume: 65 | Issue: 6 | Pages: 1272-1275

10.1111/ijd.70232 | PMID 41498280 Get It

The Impact of Senescence-Associated Secretory Phenotype (SASP) on Head and Neck Cancers: From Biology to Therapy
Alam, Md Tanjim , Mansoor, Mishfak A. M. , Golusińska-Kardach, Ewelina , Strzelczyk, Joanna Katarzyna , Rubiś, Błażej , Ashiqueali, Sarah A., Golusinska-Kardach, Ewelina , Strzelczyk, Joanna K , Rubis, Blazej , Ashiqueali, Sarah , Golusiński, Paweł , Golusiński, Wojciech , Masternak, Michal M

Mayo Clinic

Cancers | December 17, 2025 | Volume: 17 | Issue: 24 | Pages: 4024

10.3390/cancers17244024 | PMID 41463272 Get It

Cellular senescence is defined as a state of permanent cell cycle arrest, providing a natural barrier against cancer. However, senescent cells are very metabolically active and secrete a complex mixture of bioactive molecules collectively known as the senescence-associated secretory phenotype (SASP), which play a dual role in cancer biology. While the SASP can suppress tumors by facilitating immunosurveillance, it can also promote tumor progression by fostering a pro-inflammatory milieu, stimulating angiogenesis, enhancing invasiveness, and enabling immune evasion. In Head and Neck Cancers (HNCs), a highly heterogeneous group of malignancies, SASP has emerged as a critical player in disease progression and treatment resistance. Persistent DNA damage response (DDR) signaling drives SASP and thereby contributes to the progression of head and neck cancer by modulating the tumour microenvironment. It influences the tumor microenvironment (TME) by facilitating epithelial-to-mesenchymal transition (EMT), promoting cancer stem cell-like properties, and impairing the efficacy of radiotherapy, chemotherapy, and immune checkpoint inhibitors. These effects underscore the need for targeted interventions to regulate SASP activity. This review presents a comprehensive overview of the molecular mechanisms underlying SASP generation and its effects on HNCs. We discuss the dual roles of SASP in tumor suppression and progression, its contribution to therapy resistance, and emerging therapeutic strategies, including novel senolytic and senomorphic drugs. Finally, we highlight key challenges and future directions for translating SASP-targeted therapies into clinical practice, emphasizing the need for biomarker discovery, and a deeper understanding of SASP heterogeneity. By targeting the SASP, there is potential to enhance therapeutic outcomes and improve the management of HNCs.
Survival and gvhd disparities in UAE patients undergoing allo-HSCT abroad: A multicenter benchmark study
Haleeqa, Mohamed Abu, Kaabi, Fatema Al, Alam, Arif, Mheidly, Kayane, Afrooz, Imrana, Mir, Farooq Ahmed, Hasan, Riad Al, Raidullah, Emadullah, Alomari, Omer , Mohamed, Manar, ElGhazali, Gehad , Hashmi, Shahrukh K. , Syed, Naveed , Damlaj, Moussab , Khan, Azmat Ali , Mohamed, Manar

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7791-7791

10.1182/blood-2025-7791 Get It

Abstract Background: Until 2022, the United Arab Emirates (UAE) lacked in-country allogenic hematopoietic stem cell transplant (allo-HSCT) services, forcing patients abroad for curative treatment while local hematologists managed pre- and post-transplant care. This fragmented model created unique challenges in graft-versus-host disease (GVHD) monitoring and survival tracking. We present the first analysis of outcomes in this underserved population. Aims: To evaluate overall survival (OS) and GVHD rates in adults receiving allo-HSCT abroad with UAE-based follow-up, establishing benchmarks for emerging local transplant programs. Methods: Retrospective multicenter study of adults undergoing allo-HSCT outside the UAE (2009–2023) with follow-up at three tertiary centers (SSMC, SKMC, Tawam). Of 454 screened patients, we excluded pediatric cases (n=245), autologous HSCT (n=76; excluded due to distinct indications/outcomes), and rare allo-HSCT indications (n=33), focusing on the most common diagnoses: acute myeloid leukemia (AML, n=54), B/T-acute lymphoblastic leukemia (B/T-ALL, n=38), and sickle cell disease (SCD, n=8). Kaplan-Meier (KM) analysis estimated 1/3/5-year OS. Observed median survival was calculated for deceased patients. GVHD grading followed NIH consensus criteria. Log-rank tests compared subgroups (donor type). Results: Survival: AML 1/3/5-year OS: 96%/79.3%/55.5% (95% CI 48–63). KM-estimated median not reached; observed median in deceased patients: 20 months. Matched unrelated donor (MUD) recipients had inferior survival vs. matched related donor (MRD)/mismatched related donor (MMRD) (p=0.03). B-ALL: 1/3/5-year OS: 92%/76.4%/69.2% (95% CI 61–77). T-ALL (n=7): 1/3-year OS: 80%/50% (limited by small sample) SCD (n=8): 100% survival at all timepoints; no GVHD observed. GVHD: Any-grade GVHD: 68.5% (AML), 73.3% (B-ALL), 71.4% (T-ALL)—exceeding CIBMTR benchmarks (50–60%). Acute GVHD 35.2% (AML), 43.3% (B-ALL), 28.6% (T-ALL). Chronic GVHD 46.3% (AML), 40% (B-ALL), 57.1% (T-ALL). Conclusion: Despite high GVHD rates, survival outcomes support selective overseas referral for AML/B-ALL patients, particularly younger recipients. SCD results highlight the safety of HSCT in non-malignant disease. These findings underscore the need for local HSCT capacity to mitigate care fragmentation and establish a critical benchmark for UAE programs. Prospective studies should evaluate socioeconomic drivers of referral patterns and GVHD disparities.
ALPREG: A Multicenter Study of Maternal and Neonatal Outcomes Among Pregnant Women with Alport Syndrome in the United States
Allam, Krishna C, Alam, Sreyoshi Fatima , Kattah, Andrea G. , Brophy, K , Koubar, Sahar H. , Allam, Krishna C, Oliverio, Andrea L. , Rheault, Michelle N. , Nachman, Patrick H.

Mayo Clinic

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025k8b10j29 Get It